1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | Licensing Program Analyst (LPA) Sabrina Calzada arrived unannounced to complete and deliver findings to a complaint investigation received on 1/28/2022. LPA met with Fredricka Quarrie, Maureen Williams, Marlene Duncan, caregivers, who contacted the Administrator, Lani, by phone. LPA met with Glenn Bilog, Co-Administrator, who arrived at the facility around 3:30 pm.
Prior to initiating today's inspection, LPA completed required COVID-19 testing protocols and completed a daily self-screening questionnaire for symptoms of COVID-19 infection to affirm no COVID-19 related symptoms. Additionally, LPA was screened per Covid-19 precautionary measures upon entering the community. LPA ensured she applied hand sanitizer before entering the facility and the following Personal Protective Equipment (PPE) was worn: N95 mask. LPA observed (6) residents to be napping/awake in their rooms at the start of the inspection.
During the course of the investigation, the additional deficiency was observed as follows:
During a medication record review for resident (R1) on 5/26/22, it was determined that (7) tablets of a bottle of (30) of PTN Alprazolam 0.5 mg were administered to R1 from 5/15/22 through 5/26/22; however, there is no documentation to show on what days, times, etc as required per the regulation.
Per California Code of Regulations, Title 22, Division 6, Chapter 8, the following (1) deficiency is being cited on the 809D page.
Exit interview. Copy of report and appeal rights provided to Administrator. |